CheckMate 204: Nivolumab + Ipilimumab in Pts With Advanced Melanoma and Asymptomatic, Untreated Brain Metastases

June 2-6, 2017; Chicago, Illinois
First presentation of efficacy data suggests checkpoint inhibitor combination is effective in these patients, with intracranial ORR of 55%.
Format: Microsoft PowerPoint (.ppt)
File Size: 588 KB
Released: June 7, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on immunotherapy for HCC and BTCs

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: June 18, 2021

Slides on emerging guidance and data for COVID-19 vaccines in patients receiving immune checkpoint inhibitors, from Clinical Care Options (CCO)

person default Matthew Zibelman, MD Released: June 17, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of immune checkpoint inhibitors for advanced HCC

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue